Abcam, ab248880, Anti-SLD5 antibody [EPR9318] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SLD5 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9318,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Human,
Applications:Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248880 is the carrier-free version of
ab139683
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SLD5 also known as GINS4 is a subunit of the GINS complex. It has a molecular mass of approximately 22 kDa. SLD5 plays a significant role in DNA replication specifically during the initiation and elongation phases. The protein is expressed in various tissues with higher levels observed in proliferating cells. By binding to DNA replication origins SLD5 ensures the proper unwinding and loading of other replication factors.
Biological function summary
SLD5 interacts with other components of the GINS complex to form a stable structure necessary for the replication fork's progression. The GINS complex comprising SLD5 PSF1 PSF2 and PSF3 couples with other protein assemblies like CDC45 and MCM (mini chromosome maintenance) proteins. This dynamic association enables the replication machinery to effectively duplicate the genome without errors.
Pathways
SLD5 plays a part in the initiation of the DNA replication pathway. It partners with proteins like CDC45 and the MCM complex to form a replicative helicase. This assembly serves to unwound the DNA double helix facilitating replication. Furthermore interactions with ATR and ATM pathways position SLD5 within the larger network of DNA damage response ensuring any replication stress is adequately managed.
SLD5 exhibits connections with cancers such as breast cancer and colorectal cancer. Alterations in SLD5 expression can influence tumor progression by modulating cell proliferation rates. Through these pathways proteins like MCM and CDC45 are also implicated serving as key regulators in oncogenic processes where SLD5 activity expands its influence. Understanding these relationships offers insights into potential therapeutic targets for controlling abnormal cell growth.